Comparative Pharmacology
Head-to-head clinical analysis: EVISTA versus MILOPHENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVISTA versus MILOPHENE.
EVISTA vs MILOPHENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM) that binds to estrogen receptors, acting as an agonist in bone and antagonist in breast and uterine tissues.
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
60 mg orally once daily.
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 32.5 hours (range 27-39 hours) for raloxifene and its glucuronide conjugates; clinically relevant for once-daily dosing.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Raloxifene undergoes extensive glucuronidation; <0.1% excreted unchanged in urine. Approximately 95% is excreted in feces over 5 days (primarily as glucuronide conjugates). Renal elimination of unchanged drug is negligible (<0.1%).
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Category C
Category C
Selective Estrogen Receptor Modulator
Selective Estrogen Receptor Modulator